MX9705119A - Interferona modificada quimicamente. - Google Patents

Interferona modificada quimicamente.

Info

Publication number
MX9705119A
MX9705119A MX9705119A MX9705119A MX9705119A MX 9705119 A MX9705119 A MX 9705119A MX 9705119 A MX9705119 A MX 9705119A MX 9705119 A MX9705119 A MX 9705119A MX 9705119 A MX9705119 A MX 9705119A
Authority
MX
Mexico
Prior art keywords
chemically modified
modified interferon
consensus interferon
interferon
conjugated
Prior art date
Application number
MX9705119A
Other languages
English (en)
Other versions
MXPA97005119A (es
Inventor
David S Collins
Jennifer Lin-Chun Liu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX9705119A publication Critical patent/MX9705119A/es
Publication of MXPA97005119A publication Critical patent/MXPA97005119A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion se refiere a interferona consensual modificada químicamente, que tiene uno o más ligando(s) de glicosido conjugados a la interferona consensual. La invencion también se refiere a composiciones farmacéuticas que contienen tales análogos y métodos de tratamiento usando las composiciones de la invencion.
MXPA/A/1997/005119A 1995-01-13 1997-07-08 Interferona modificada quimicamente MXPA97005119A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37247895A 1995-01-13 1995-01-13
US372478 1995-01-13
PCT/US1996/000323 WO1996021468A2 (en) 1995-01-13 1996-01-11 Chemically modified interferon

Publications (2)

Publication Number Publication Date
MX9705119A true MX9705119A (es) 1997-10-31
MXPA97005119A MXPA97005119A (es) 1998-07-03

Family

ID=

Also Published As

Publication number Publication date
ZA96206B (en) 1996-08-19
KR19980701814A (ko) 1998-06-25
WO1996021468A3 (en) 1996-09-12
EP0804248A2 (en) 1997-11-05
BR9607599A (pt) 1998-06-09
JPH10513440A (ja) 1998-12-22
WO1996021468A2 (en) 1996-07-18
IL116730A0 (en) 1996-05-14
AU4751896A (en) 1996-07-31
CA2209557A1 (en) 1996-07-18

Similar Documents

Publication Publication Date Title
WO1996021468A3 (en) Chemically modified interferon
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
GR3026758T3 (en) Lactobacillus strains of human origin, their compositions and uses thereof
GEP20043375B (en) APRIL-Receptor (BCMA) and Use Thereof
UA43348C2 (uk) Водна фармацевтична композиція, що включає фактор росту нерва (варіанти) та ліофілізований фармацевтичний склад
ZA965294B (en) Substituted 4-phenylaminothiazoles, their process of preparation and the pharmaceutical compositions containing them.
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
IL127918A0 (en) Novel amino sugar and related sugar derivatives of indolylopyrrolocarbazoles their use as antitumor agents and pharmaceutical formulations
HU9403343D0 (en) New pharmaceutical uses of krill enzymes
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
WO1996022305A3 (en) Modified peptides
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
ZA966047B (en) Therapeutic agents.
BG102667A (en) Diosgenine-containing composition
AU6849198A (en) Neurotrypsin
MY114693A (en) Substituted benzenesulfonylureas and thioureas,processes for their preparation,their use for the production of pharmaceutical preparations, and pharmaceutical preparation containing them
EP0715519A4 (en) IMMUNOMODULATIVE, ANTI-INFLAMMATORY AND ANTIPROLIFERATIVE COMPOUNDS: 5,6-DIDEOXY, 5-AMINO DERIVATIVES OF IDOSE AND 6-DEOXY, 6-AMINO DERIVATIVES OF GLUCOSE
MY115795A (en) Substituted benzenesulfonylureas and -thioureas, processes for their preparation and use of pharmaceutical preparations based on these compounds, and medicaments containing them
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.
IT1269740B (it) Derivati di combretastatine ad attivita' anti-tumorale e procedimento per la loro preparazione
UA32580C2 (uk) Засіб для лікування паралітичної непрохідності кишечнику
IT1280010B1 (it) Composizione farmaceutica a base di un complesso agente terapeutico/ matrice polimerica dotato di migliorate caratteristiche disapore